Barres B, et al. - In this observational retrospective study on 1,093 patients treated between 1995 and 2010, authors assessed the predictive ability of stimulated thyroglobulin and thyroglobulin reduction index (TRI) for long-term remission in patients with differentiated thyroid cancer (DTC) treated by thyroidectomy and radioactive iodine (RAI) remnant ablation. They recognized lymph node invasion, preablation stimulated thyroglobulin, stimulated thyroglobulin, and TRI as independent predictive factors affecting the rate of disease persistence/recurrence following primary management. They concluded elevated TRI (more than 60%) for the entire cohort and 62.5% for locally advanced disease (T3/T4, N1) as a sensitive predictor for an excellent response.